Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

629
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
629
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
DNA Damage Can Stall the Cell Cycle02:37

DNA Damage Can Stall the Cell Cycle

2.7K
2.7K
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.7K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

9.3K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autocrine TGFβ2 enforces a transcriptionally hybrid cell state in Ewing sarcoma.

Science advances·2026
Same author

Pathogenic Germline PALB2 and RAD50 Variants in Patients With Relapsed Ewing Sarcoma.

Pediatric blood & cancer·2026
Same author

ALARA in Antimicrobial Stewardship: Adapting Radiation Safety Principles to Address Antibiotic Overuse.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

Molecular Characterization Informs Prognosis in Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025
Same author

An opportunity to save? SBRT is less costly than IMRT for intermediate-risk prostate cancer.

Urologic oncology·2025
Same author

Future Directions and Priorities for Cellular Therapy in Sarcoma: A Report from the Strategic Advances in Sarcoma Science Cell Therapy Breakout.

Cancers·2025

Related Experiment Video

Updated: Aug 18, 2025

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.5K

Harnessing immunomodulation during DNA damage in Ewing sarcoma.

Jessica D Daley1, Adam C Olson2, Kelly M Bailey1,3

  • 1Department of Pediatrics, Division of Pediatric Hematology and Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States.

Frontiers in Oncology
|December 9, 2022
PubMed
Summary
This summary is machine-generated.

Innovative therapies are crucial for metastatic Ewing sarcoma (a bone cancer). This review explores DNA damage repair defects and their impact on treatment, including radiation and immunotherapy combinations.

Keywords:
DNA damageEwing sarcomaimmunobiologyimmunomodulationradiationrelapse

More Related Videos

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

2.8K
Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.3K

Related Experiment Videos

Last Updated: Aug 18, 2025

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
12:03

In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis

Published on: December 9, 2016

12.5K
Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis
09:58

Mapping the Structure-Function Relationships of Disordered Oncogenic Transcription Factors Using Transcriptomic Analysis

Published on: June 27, 2020

2.8K
Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells
12:08

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

9.3K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Ewing sarcoma is a primary bone tumor predominantly affecting adolescents, characterized by poor outcomes in metastatic and relapsed stages.
  • The tumor is recognized as 'BRCAness,' exhibiting diverse DNA damage repair (DDR) defects, including the EWSR1::FLI1 fusion oncoprotein, somatic mutations, and germline variations.
  • Understanding the cumulative effect of these DDR defects is vital for tailoring effective therapeutic strategies.

Purpose of the Study:

  • To review innovative therapeutic approaches for Ewing sarcoma, focusing on DNA-damaging agents.
  • To explore the role of DNA damage in modulating the tumor immune microenvironment.
  • To identify opportunities for combining DNA-damage-directed therapies with immunotherapy, particularly in metastatic and relapsed disease.

Main Methods:

  • Literature review of studies on Ewing sarcoma, DNA damage repair mechanisms, and immunotherapy.
  • Analysis of the interplay between DNA damage pathways and the tumor immune microenvironment.
  • Examination of the potential of DNA-damaging agents, including radiation, as therapeutic modulators.

Main Results:

  • Ewing sarcoma exhibits a spectrum of DDR defects, influencing treatment response.
  • DNA damage can modulate the tumor immune microenvironment, suggesting potential for combination therapies.
  • Radiation therapy is a key DNA-damaging agent with potential to enhance immunotherapy efficacy.

Conclusions:

  • Targeting DDR defects and leveraging DNA-damaging agents, especially in combination with immunotherapy, offers promising avenues for treating Ewing sarcoma.
  • Further research into the synergistic effects of DNA-damage/immunotherapy combinations is warranted for metastatic and relapsed Ewing sarcoma.
  • Understanding the tumor's immune microenvironment is critical for optimizing treatment strategies in Ewing sarcoma.